News >

PD-L1/CTLA-4 Dual Blockade Shows Promise in NSCLC

Jason M. Broderick @jasoncology
Published: Friday, Feb 12, 2016

Dr Scott J. Antonia

Scott J. Antonia, MD, PhD

A combination checkpoint blockade with the PD-L1 inhibitor durvalumab and the anti–CTLA-4 agent tremelimumab induced a response rate of 23% in patients with advanced non–small cell lung cancer (NSCLC), according to phase Ib data published in The Lancet Oncology.

Antonia S, Goldberg SB, Balmanoukian A, et al. Lancet Oncol. Safety and antitumor activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicenter, phase 1b study [published online February 5, 2016]. Lancet Oncol. doi:10.1016/S1470-2045(15)00544-6.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Online Medical Crossfire®: 5th Annual Miami Lung Cancer ConferenceMay 30, 20196.5
Community Practice Connections™: Working Group for Changing Standards in EGFR-Mutated Lung Cancers: Real-World Applications of the Evidence for NursesJun 29, 20191.5
Publication Bottom Border
Border Publication